We included the systematic review by Geng et al.7, published in 2020 in Plos One, for the synthesis of evidence, since it is aimed to assess the safety and efficacy of paricalcitol vs. calcitriol in the management of SHPT in patients with CKD 5D regarding PTH, calcium, phosphorus levels and adverse events. Here, PTH is linked to chronic kidney disease.